A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA Greenlights Novel EGFR Exon 20 Inhibitor for First-Line Metastatic NSCLC Treatment, Marking a Milestone in Lung Cancer Care

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Janssen Pharmaceutical Advances Rare Disease Research and Gene Therapy, Gains Breakthrough Designation in China

Janssen Pharmaceutical Companies Secures FDA Approval for NSCLC Therapy and Champions Cardiac Health Equity

Janssen Pharmaceutical Drives Industry Innovation with New Ulcerative Colitis Research, Gene Therapy Discussions, Advances in Lung Cancer Therapeutics, and Initiatives on Health Equity

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count